KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance. PMID 36517408 · Eur Urol Focus · 2023-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Establishment of prognostic nomogram for T1N0M0 glottic squamous cell carcinoma: an SEER database analysis. PMID 36454384 · Eur Arch Otorhinolaryngol · 2023-May The study is a retrospective database analysis, not a randomized clinical trial of a drug intervention. It lacks explicit phase information and does not test a drug as the primary intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intermittent Pringle maneuver combined with controlled low Central venous pressure prolongs hepatic hilum occlusion time in patients with hepatocellular carcinoma complicated by post hepatitis B cirrhosis: a randomized controlled trial. PMID 36384398 · Scand J Gastroenterol · 2023-May The study is a randomized controlled trial in oncology (hepatocellular carcinoma) but compares two surgical/anesthetic techniques (occlusion times) without any drug intervention. The primary endpoints are perioperative safety and surgical outcomes (operation time, bleeding, infection), not time-to-event efficacy endpoints like overall survival or progression-free survival. No Kaplan-Meier curves or hazard ratios are mentioned. Therefore, it does not meet the criteria for inclusion in the oncology KM digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Short-term postoperative efficacy of steroid-eluting stents for eosinophilic chronic rhinosinusitis with nasal polyps: A randomized clinical trial. PMID 36086876 · Int Forum Allergy Rhinol · 2023-May 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Virtual monitoring for stable chronic hepatitis B patients does not reduce adherence to medications: A randomised controlled study. PMID 33461398 · J Telemed Telecare · 2023-May The record is a randomized trial in human oncology patients with a drug intervention, but it does not meet the primary inclusion criterion of having a primary/key secondary time-to-event efficacy endpoint. The endpoints are adherence and incidence rates, not time-to-event outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effect of nursing intervention on self-care self-efficacy and genes related to anxiety in patients with bone marrow transplantation. PMID 37300683 · Cell Mol Biol (Noisy-le-grand) · 2023-Mar-31 The record describes a randomized, controlled nursing intervention study in leukemia patients undergoing bone marrow transplantation. It is human and oncology-related, and presents original results. However, it is ineligible because: (1) the intervention is non-drug (health promotion strategies/nursing), (2) the endpoints are self-efficacy scores and gene expression, not time-to-event efficacy endpoints, and (3) the trial phase is not reported and is unlikely to be Phase III/IIIb or Phase II/III given the study design.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant Pseudomonas aeruginosa mannose-sensitive hemagglutinin (PA-MSHA) and chemotherapy versus placebo plus chemotherapy in patients with HER2-negative breast cancer: a randomized, controlled, double-blind trial. PMID 37082658 · Ann Transl Med · 2023-Mar-31 The trial is a randomized, controlled, double-blind study in HER2-negative breast cancer with a drug intervention (PA-MSHA) and reports original results. However, the primary endpoint is objective response rate (ORR), which is not a time-to-event endpoint like OS, PFS, DFS, etc. Although survival outcomes (DFS, RFS, OS) are mentioned, they are reported as secondary or exploratory findings and are not designated as primary/key secondary endpoints in the trial design. Additionally, the trial phase is not explicitly stated as Phase III or Phase II/III in the title or abstract; it is described as a 'randomized, controlled, double-blind clinical trial' without a definitive phase label, preventing confirmation of the required phase criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Antidepressants for the treatment of depression in people with cancer. PMID 36999619 · Cochrane Database Syst Rev · 2023-Mar-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Standard follow-up after curative surgery for advanced gastric cancer: secondary analysis of a multicentre randomized clinical trial (KLASS-02). PMID 36723976 · Br J Surg · 2023-Mar-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Chemoembolization combined radiofrequency ablation vs. chemoembolization alone for treatment of beyond the Milan criteria viable hepatocellular carcinoma (CERFA): study protocol for a randomized controlled trial. PMID 36978150 · Trials · 2023-Mar-28 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Interventions for weight reduction in obesity to improve survival in women with endometrial cancer. PMID 36971688 · Cochrane Database Syst Rev · 2023-Mar-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
SAFESTEREO: phase II randomized trial to compare stereotactic radiosurgery with fractionated stereotactic radiosurgery for brain metastases. PMID 36964529 · BMC Cancer · 2023-Mar-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Establishment and validation of a prognostic nomogram for patients with early-onset stage I-II colon cancer. PMID 36964525 · World J Surg Oncol · 2023-Mar-24 This is an observational prognostic model development study using SEER database, not an interventional randomized controlled trial of a drug. The 'randomized' label in metadata refers to splitting data for training/validation, not treatment randomization. There is no confirmed drug intervention or trial phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
HOPPSA update: changes in the study protocol of Hysterectomy and OPPortunistic SAlpingectomy, a registry-based randomized controlled trial. PMID 36959664 · Trials · 2023-Mar-24 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Home-based cardio-oncology rehabilitation using a telerehabilitation platform in hematological cancer survivors: a feasibility study. PMID 36959613 · BMC Sports Sci Med Rehabil · 2023-Mar-23 The record is a single-arm feasibility study of a non-drug intervention (telerehabilitation-based exercise) in hematological cancer survivors, with no time-to-event endpoints. It fails multiple key eligibility criteria: it is not randomized, not a definitive Phase II/III or III/IIIb trial, lacks a drug intervention, and does not report time-to-event outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of pecto-intercostal fascial block combined with rectus sheath block for postoperative pain management after cardiac surgery: a randomized controlled trial. PMID 36959543 · BMC Anesthesiol · 2023-Mar-23 The study is a randomized controlled trial in humans with original results, but it is non-oncology (cardiac surgery pain management), does not involve a drug-containing intervention (nerve blocks are procedures), and lacks a time-to-event efficacy endpoint (primary outcome is opioid consumption).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effectiveness of high-flow nasal cannulae compared with noninvasive positive-pressure ventilation in preventing reintubation in patients receiving prolonged mechanical ventilation. PMID 36949116 · Sci Rep · 2023-Mar-22 This is a randomized trial in intensive care patients evaluating respiratory support methods (high-flow nasal cannula vs. noninvasive positive-pressure ventilation) for preventing reintubation. It is not a study of human malignant neoplasm and does not involve a drug-containing intervention. The primary endpoint is reintubation, a clinical event, not a standard oncology time-to-event efficacy endpoint like OS, PFS, or DFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Optimising psychological treatment for pain after breast cancer: a factorial design study protocol in Denmark. PMID 36948567 · BMJ Open · 2023-Mar-22 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C). PMID 36941575 · BMC Cancer · 2023-Mar-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Protocol for a pragmatic cluster randomised controlled trial assessing the clinical effectiveness and cost-effectiveness of Electronic RIsk-assessment for CAncer for patients in general practice (ERICA). PMID 36940950 · BMJ Open · 2023-Mar-20 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. PMID 36921335 · J Clin Oncol · 2023-Mar-20 The study is an eligible oncology RCT with a drug intervention and primary results, but it lacks a primary or key secondary time-to-event endpoint (e.g., OS, PFS). The primary endpoint is objective response rate. The phase is not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. PMID 36512738 · J Clin Oncol · 2023-Mar-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Fully constrained acetabular liner vs. dual mobility hip joint in the surgical treatment of metastatic bone disease of the hip: study protocol for a randomized, open-label, two-arm, non-inferiority trial evaluating the post-operative hip dislocation rate. PMID 36934286 · Trials · 2023-Mar-18 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study). PMID 36426809 · Oncologist · 2023-Mar-17 The trial is a randomized Phase III study in oncology patients with a drug intervention, but its primary endpoint is a proportion (requiring high-dose opioids), not a time-to-event outcome like OS, PFS, DFS, or a Kaplan-Meier/HR analysis. Therefore, it does not meet the required criteria for inclusion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma. PMID 36922497 · Nat Commun · 2023-Mar-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-Small Cell Lung Cancer Patients Unfit for ConcurrEnt RAdio-Chemotherapy: Early Analysis of the START-NEW-ERA Non-Randomised Phase II Trial. PMID 36288758 · Int J Radiat Oncol Biol Phys · 2023-Mar-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Predicting Malignant Ventricular Arrhythmias Using Real-Time Remote Monitoring. PMID 36889873 · J Am Coll Cardiol · 2023-Mar-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Corrigendum to: Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C. PMID 36749184 · Neuro Oncol · 2023-Mar-14 This is a corrigendum (published erratum) to a phase III randomized trial. It is not an original formal-result report of a trial. The title indicates the study was randomized and phase III with a drug intervention (temozolomide), but the provided metadata contains no abstract, publication of results, or any mention of time-to-event endpoints like OS, PFS, or HR. Therefore, it fails the criteria for being an original result report with a primary/key secondary time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial. PMID 36622702 · Clin Cancer Res · 2023-Mar-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406). PMID 36622694 · Clin Cancer Res · 2023-Mar-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of remote ischemic preconditioning on postoperative gastrointestinal function in patients undergoing laparoscopic colorectal cancer resection. PMID 36899148 · Int J Colorectal Dis · 2023-Mar-11 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Multimodal Physical Exercise and Functional Rehabilitation Program in Oncological Patients with Cancer-Related Fatigue-A Randomized Clinical Trial. PMID 36981846 · Int J Environ Res Public Health · 2023-Mar-10 The study is an oncology RCT evaluating a non-drug physical exercise/rehabilitation intervention for cancer-related fatigue, with no time-to-event efficacy endpoint reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Overall morbidity after total minimally invasive keyhole oesophagectomy versus hybrid oesophagectomy (the MICkey trial): study protocol for a multicentre randomized controlled trial. PMID 36899404 · Trials · 2023-Mar-10 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial. PMID 36657089 · J Clin Oncol · 2023-Mar-10 The trial is randomized, human, oncologic, drug-interventional, and reports original results, but its primary and secondary endpoints (2-year residual/recurrence rate, surgical morbidity, histopathologic stage, etc.) are not the required time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP) with associated Kaplan-Meier or HR. The deterministic review signal 'no_time_to_event_signal' is correct.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Roussel M, Lauwers-Cances V, Macro M, et al. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood. 2022;139(18):2747-2757. PMID 36893003 · Blood · 2023-Mar-09 The publication type indicates a Phase III randomized controlled trial in oncology (multiple myeloma), but the abstract is missing, and the title/deterministic review signals provide no reliable information about a drug-containing intervention, a time-to-event efficacy endpoint, or an original formal-result report. Without an abstract or full text, key eligibility criteria (human, drug intervention, time-to-event endpoint, original result) cannot be established.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A prediction model for predicting the risk of acute respiratory distress syndrome in sepsis patients: a retrospective cohort study. PMID 36890503 · BMC Pulm Med · 2023-Mar-08 The study is a retrospective cohort analysis predicting ARDS risk in sepsis patients. It is not an oncology trial, does not involve a drug intervention as the primary focus, does not have a time-to-event efficacy endpoint (like OS, PFS, etc.), and while the publication type is listed as 'Randomized Controlled Trial', the study design is a retrospective analysis of a database, not a randomized trial with a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer. PMID 36884035 · Cochrane Database Syst Rev · 2023-Mar-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC. PMID 36882775 · BMC Med · 2023-Mar-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
[Analysis of success rate of organoid construction of nasopharyngeal carcinoma by first-day suspension method]. PMID 36878504 · Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi · 2023-Mar-07 The record describes a randomized controlled trial comparing two laboratory methods for constructing nasopharyngeal carcinoma patient-derived organoids. While it is a randomized, human, oncology study, it is not a Phase III/IIIb or Phase II/III therapeutic trial. The primary endpoint is a technical success rate, not a time-to-event efficacy endpoint. The intervention is a non-drug laboratory method. Therefore, it does not meet the core eligibility criteria for the Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062. PMID 36533429 · Jpn J Clin Oncol · 2023-Mar-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL). PMID 36879257 · BMC Urol · 2023-Mar-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Prospective and Cross-sectional Associations of the Rectal Tissue Microbiome with Colorectal Adenoma Recurrence. PMID 36525653 · Cancer Epidemiol Biomarkers Prev · 2023-Mar-06 The study is a randomized trial on colorectal adenoma recurrence, but it does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The intervention is dietary (non-drug). The primary outcome is adenoma recurrence measured via logistic regression, not Kaplan-Meier analysis or hazard ratio for time-to-event data.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Relationships between Obesity, Exercise Preferences, and Related Social Cognitive Theory Variables among Breast Cancer Survivors. PMID 36904284 · Nutrients · 2023-Mar-04 The record describes a cross-sectional analysis of baseline relationships between obesity and behavioral/psychological variables within a randomized controlled trial of physical activity for breast cancer survivors. It does not report a drug intervention or a time-to-event efficacy endpoint. Therefore, it does not meet the criteria for a drug-containing Phase III or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial. PMID 36870941 · BMC Cancer · 2023-Mar-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Assessment of Autologous Blood marker localIzation and intraoperative coLonoscopy localIzation in laparoscopic colorecTal cancer surgery (ABILITY): a randomized controlled trial. PMID 36869328 · BMC Cancer · 2023-Mar-03 干预为非药物单独策略,未满足药物干预要求。
H L B
旧查询独有 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Development and validation of prognostic nomogram for patients with metastatic gastric adenocarcinoma based on the SEER database. PMID 36862921 · Medicine (Baltimore) · 2023-Mar-03 The study is a retrospective prognostic nomogram development using SEER data, not a randomized trial of a drug intervention. Although it is tagged as 'Randomized Controlled Trial' in publication types, the study itself describes random split of data into training/validation sets for model development, not a therapeutic RCT. There is no Phase III/IIIb or Phase II/III trial evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. PMID 36856617 · N Engl J Med · 2023-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
An Unsupervised Machine Learning Approach to Evaluating the Association of Symptom Clusters With Adverse Outcomes Among Older Adults With Advanced Cancer: A Secondary Analysis of a Randomized Clinical Trial. PMID 36947036 · JAMA Netw Open · 2023-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes. PMID 36857596 · JNCI Cancer Spectr · 2023-Mar-01 The study is not eligible because the primary drug intervention under investigation for cancer outcomes is metformin, which is not randomized in this analysis (it's an observational exposure within the trial). The randomized component (aspirin vs. placebo) is used to assess effect modification, not as the primary drug intervention for cancer endpoints. Additionally, the report is a secondary analysis within a broader trial (ASPREE), not a primary report of a Phase III oncology trial with a drug intervention as the main comparator.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of CalliSpheres® microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial. PMID 36794998 · Radiol Oncol · 2023-Mar-01 The study meets most criteria (oncology, human, randomized, time-to-event, drug intervention, original result) but does not explicitly establish a Phase III/IIIb or Phase II/III designation in the provided metadata. The deterministic review flags phase evidence as unclear. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -